Neurocognitive effects of agomelatine treatment in schizophrenia patients suffering from comorbid depression: results from the AGOPSYCH study
AbstractBackgroundCognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
August 2018
|
| In: |
Journal of clinical psychopharmacology
Year: 2018, Jahrgang: 38, Heft: 4, Pages: 357-361 |
| ISSN: | 1533-712X |
| DOI: | 10.1097/JCP.0000000000000909 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1097/JCP.0000000000000909 Verlag: insights.ovid.com 
|
| Verfasserangaben: | Susanne Englisch, Hanna Jung, Sarah Eisenacher, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Andreas Meyer-Lindenberg and Mathias Zink |
| Zusammenfassung: | AbstractBackgroundCognitive impairment in schizophrenia is highly disabling and remains one of the major therapeutic challenges. Agomelatine (AGO), an agonist at melatonergic MT1/MT2 receptors and antagonist at 5-HT2C receptors, increases dopamine and norepinephrine in the prefrontal cortex and may |
|---|---|
| Beschreibung: | Gesehen am 30.01.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1533-712X |
| DOI: | 10.1097/JCP.0000000000000909 |